Vici Venous Stent

2019: Announcement

At the beginning of May, 2019 the Boston Scientific company provided the system of VICI Venous Stent stents for treatment of occlusion of podvzdoshno-femoral veins taking into account unique features of venous anatomy.

The device was developed by Veniti company - one of the producers purchased by Boston Scientific in 2018 for $108 million.

VICI Venous Stent stents

Obstruction of podvzdoshno-femoral veins is usually connected with blood clot or compression of veins by other structures. Endovascular treatment of this pathology is directed to recovery of a normal blood-groove from legs. As podvzdoshno-femoral veins are located deeply in a small basin, they can significantly be squeezed by other anatomic educations, such as right general podvzdoshny artery. Therefore the system of VICI stents was designed as the cylinder, strong and steady against crush and twisting, capable to recover a blood-groove taking into account these features.

Regulatory bodies approved the device on the basis of results of the prospektivny multicenter research VIRTUS in which 170 patients participated. The stent was estimated at VIRTUS on the predeterminated objective performance indicators at patients with clinically significant obstruction of podvzdoshno-femoral veins.

Boston Scientific notes that obstruction of ileofemoralny veins in a varying degree meets almost at 40% of the population of the USA and Mei-Turner's syndrome can be connected with such statuses as thrombosis of deep veins, a posttrombotichesky syndrome and compression diseases, for example. At patients with venous obstruction blood stands in a venous bed of legs, causing pain, hypostasis and skin ulcers and significantly reducing quality of life. The VICI stent provided to doctors the therapy option created taking into account anatomic features of a venous system to improve results of treatment and quality of life of patients.^[1]

Notes